Admescope launches in vitro tox services
2 September 2013
Admescope is pleased to announce the launch of in vitro toxicology services. So far we have been well known for high-quality tailor-made ADME services, and the new services provide a valuable addition to our strong existing service portfolio.
Our goal is to provide cost-efficient early stage safety screening services, to save time and money in later stages of the development. Now we are launching services for cytotoxicity, cardiotoxicity and genotoxicity screening, and some other new in vitro tox services will be available soon as well; we will keep you updated!
We now offer several methods to evaluate drug induced cytotoxicity. In addition to the traditional assay measuring release of lactate dehydrogenase (LDH) into the cell culture medium, also assays utilizing DNA-binding fluorescent dyes or dead cell protease activities to indicate the amount of cell death are available. The number of viable cells can be determined simultaneously by quantifying the amount of ATP present.
Predictor™ hERG fluorescence polarization assay allows high-throughput hERG liability screening in 384-well plate format. The assay utilizes hERG channel binding red-shifted fluorescent tracer, which can be displaced in the presence of competing compounds, leading to change in the fluorescence polarization. The data correlates well with patch-clamp studies offering cost-efficient way to evaluate cardiosafety early in the drug discovery process.
Mutagenic potential of the compound can be assessed with AMES MPF™ in 384-well plate format. The assay is fast and efficient requiring lower amount of compounds and yet provides excellent correlation with traditional agar-based Ames test. Currently we provide the assay with Salmonella typhimurium TA98/TA100 strains, and other strains will be available soon.
As part of our service portfolio we also have assays for analysis of reactive metabolites and time-dependent inhibition, which richly complement these new in vitro tox services.